Clinical Trials
104 trialsNCT06379399 2024-04-23
Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC
Zhejiang Cancer Hospital
Phase 1/2 Unknown
NCT06225622 2024-03-19
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital
Phase 1 Unknown
NCT03024489 2024-03-15
Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma
Mahidol University
Phase 1/2 Unknown
NCT05291156 2024-02-01
CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy
University of Campania Luigi Vanvitelli
Phase 2 Unknown
NCT06101394 2024-01-25
RECOGNISE
University of Turin, Italy
Phase 2 Unknown
NCT06107114 2023-11-22
CZCNRHNSCC
Sun Yat-sen University
Phase 2 Unknown
NCT00997009 2023-11-14
MITO CERV 2
National Cancer Institute, Naples
Phase 2 Unknown
NCT04034459 2023-11-14
AIO-KRK-0116
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT02624128 2023-11-13
V-CHANCE
National Cancer Institute, Naples
Phase 2 Unknown
NCT06118047 2023-11-07
COSTIC
Sun Yat-sen University
Phase 2 Unknown
NCT06081582 2023-10-13
Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT04984369 2023-08-21
The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment
Shanghai Henlius Biotech
Phase 2 Unknown
NCT04262635 2023-08-02
C-CLASSIC
Sun Yat-sen University
Phase 3 Unknown
NCT03284502 2023-08-01
HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Unknown
NCT04189055 2023-06-12
CETIDYL
Hôpital Franco-Britannique-Fondation Cognacq-Jay
Phase 2 Unknown
NCT05160896 2023-06-08
SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT05873972 2023-05-24
Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient
Fudan University
Phase NA Unknown
NCT03391934 2023-04-05
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer
Cinnagen
Phase 3 Unknown
NCT05799443 2023-04-05
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05278351 2023-03-31
Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05774964 2023-03-20
Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT05751512 2023-03-02
A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
Shanghai Miracogen Inc.
Phase 3 Unknown
NCT05684211 2023-02-01
A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer
Shanghai Celfuture Biotech Co., Ltd.
Phase 2 Unknown
NCT01855451 2022-11-18
HPVOropharynx
Trans Tasman Radiation Oncology Group
Phase 3 Unknown
NCT05497336 2022-09-30
A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Unknown
NCT05155124 2022-09-13
Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT05019534 2022-05-19
Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
West China Hospital
Phase 1 Unknown
NCT03457896 2022-03-31
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
NSABP Foundation Inc
Phase 2 Unknown
NCT02675946 2022-01-26
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Curegenix Inc.
Phase 1 Unknown
NCT05103020 2021-11-02
Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases
Yonsei University
Phase 2 Unknown
NCT05074966 2021-10-12
The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts
ChineseAMS
Phase 3 Unknown
NCT02826837 2021-10-06
LEAC-102 for Advanced Colorectal Cancer
Taiwan Leader Biotech Corp.
Phase 1/2 Unknown
NCT04241731 2021-08-30
A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT04466254 2021-08-23
Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2 Unknown
NCT03727763 2021-08-19
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT04872634 2021-07-21
SNK_ASTER
NKMAX Co., Ltd.
Phase 1/2 Unknown
NCT03552406 2021-05-06
Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors
ISU Abxis Co., Ltd.
Phase 1 Unknown
NCT02942706 2021-04-30
Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC
Ruijin Hospital
Phase 2/3 Unknown
NCT04832776 2021-04-06
FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases
Fudan University
Phase 2 Unknown
NCT04833036 2021-04-06
c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI
Fudan University
Phase 2 Unknown
NCT02054442 2021-03-12
COMMENCE
Radboud University Medical Center
Phase 1/2 Unknown
NCT04668976 2020-12-21
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Benaroya Research Institute
Phase 2 Unknown
NCT03608046 2020-10-22
AVETUXIRI
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Unknown
NCT04525326 2020-08-25
Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases
Fudan University
Phase 3 Unknown
NCT04509635 2020-08-12
Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis
Fudan University
Phase 3 Unknown
NCT02123381 2020-03-17
Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT03491709 2019-10-31
A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC
Dragonboat Biopharmaceutical Company Limited
Phase 1 Unknown
NCT01923987 2019-09-20
Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis
Korea Cancer Center Hospital
Phase 2 Unknown
NCT01802645 2019-09-11
CELIM2
Technische Universität Dresden
Phase 2 Unknown
NCT03944252 2019-07-26
CARACAS
Gruppo Oncologico del Nord-Ovest
Phase 2 Unknown